Used as a key intermediate in the synthesis of proton pump inhibitors (PPIs), particularly in the production of tenatoprazole and related anti-ulcer agents. Its structure supports the inhibition of gastric acid secretion by targeting the H+/K+-ATPase enzyme in the stomach lining. Due to the presence of trifluoroethoxy and benzimidazole moieties, it exhibits enhanced metabolic stability and binding affinity, making it valuable in developing long-acting PPIs for treating gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. The hydrate form improves handling and solubility during pharmaceutical processing.